Fracture risk from psychotropic medications: A population-based analysis

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 384-391

  Bolton, James M ^a,d   Metge, Colleen ^b   Lix, Lisa ^c   Prior, Heather ^c   Sareen, Jitender ^a,c   Leslie, William D ^c  

^a Department of Psychiatry ^*  (Canada)

^b Faculty of Pharmacy   (Italy)

^c UNIVERSITY OF MANITOBA   (Canada)

^d FRCPC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; LITHIUM; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; AGING; ARTICLE; ASSOCIATION; BONE FRAGILITY; COMORBIDITY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG USE; FEMALE; FRAGILITY FRACTURE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; CANADA; CASE CONTROL STUDY; FRACTURE; MENTAL DISEASE; MIDDLE AGED; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; MALE; MANITOBA; MENTAL DISORDERS; MIDDLE AGED; RISK FACTORS;

EID: 54449099520     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817d5943     Document Type: Article

References (72)

1. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-2018.
2. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon-General. Rockville: Office of the Surgeon General; 2004.
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-1767.
4. Burge R, wson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
5. Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007;30:171-184.
6. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188-194.
7. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br JPsychiatry. 2007;190:129-134.
8. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167:1240-1245.
9. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167:1246-1251.
10. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin- reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303-1307.
11. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am JEpidemiol. 2003;158:77-84.
12. Schneeweiss S, Wang PS. Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. JClin Psychopharmacol. 2004;24:632-638.
13. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17:807-816.
14. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363-369.
15. Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155:1801-1807.
16. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med. 2004; 164:1567-1572.
17. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch InternMed. 2003;163:949-957.
18. Wagner AK, Ross-Degnan D, Gurwitz JH, et al. Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med. 2007;146:96-103.
19. Hugenholtz GW, Heerdink ER, van Staa TP, et al. Risk of hip/femur fractures in patients using antipsychotics. Bone. 2005;37:864-870.
20. Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol. 1998;148:887-892.
21. Jacqmin-Gadda H, Fourrier A, Commenges D, et al. Risk factors for fractures in the elderly. Epidemiology. 1998;9:417-423.
22. Wilting I, de Vries F, Thio BM, et al. Lithium use and the risk of fractures. Bone. 2007;40:1252-1258.
23. Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif Tissue Int. 2005;77:1-8.
24. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000;157:1379-1389.
25. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335:1176-1181.
26. Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry. 2005;162:162-167.
27. Roos NP, Shapiro E. Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care. 1999;37:JS10-JS14. Anatomical Therapeutic Chemical (ATC) classification index. Oslo: WHO Collaboration Centre for Drugs Statistics Methodology; 2004.
28. Kozyrskyj AL, Mustard CA. Validation of an electronic, population- based prescription database. Ann Pharmacother. 1998;32:1152-1157.
29. Robinson JR, Young TK, Roos LL, et al. Estimating the burden of disease. Comparing administrative data and self-reports. Med Care. 1997;35:932-947.
30. Jebamani LS, Burchill CA, Martens PJ. Using data linkage to identify First Nations Manitobans: technical, ethical, and political issues. Can J Public Health. 2005;96:S28-S32.
31. Starfield B, Weiner J, Mumford L, et al. Ambulatory care groups: a categorization of diagnoses for research and management. Health ServRes. 1991;26:53-74.
32. Reed M, Demeter S, Lix LM, et al. Is there an association between socioeconomic factors and the per-capita utilization of selected diagnostic imaging modalities? In: Finlayson G, Leslie WD, MacWilliam L, eds. Diagnostic Imaging Data in Manitoba-Assessment and Applications. Winnipeg, MB: Manitoba Centre for Health Policy; 2004.
33. Rosholm JU, Andersen M, Gram LF. Are there differences in the use of selective serotonin uptake receptors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol. 2001;56:923-929.
34. Gichangi A, Andersen M, Kragstrup J, et al. Analysing duration of episodes of pharmacological care: an example of antidepressant use in Danish general practice. Pharmacoepidemiol Drug Saf. 2006;15:167-177.
35. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Available at: http://www.whocc.no/atcdd/. Accessed September 23, 2007.
36. van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture riskprediction among men andwomen. Bone. 2002;31:508-514.
37. Martens P, Fransoo R, McKeen N, et al. Patterns of Regional Mental Illness Disorder Diagnoses and Service Use in Manitoba: A Population-Based Study. Winnipeg, MB: Manitoba Health; 2004.
38. Ross HE, Lin E, Cunningham J. Mental health service use: a comparison of treated and untreated individuals with substance use disorders in Ontario. Can J Psychiatry. 1999;44:570-576.
39. Mustard CA, Derksen S, Tataryn D. Intensive use of mental health care. Can J Psychiatry. 1996;41:93-101.
40. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45:1330-1337.
41. Manitoba Centre for Health Policy. Income quintiles based on the 1996 census. Concept Dictionary 2007. Available at: http:www.umanitoba.ca/centres/ mchp. Accessed March 24, 2007.
42. SAS Institute Inc. Base SAS 9.1 Procedures Guide. Cary, NC: SAS Publishing; 2004.
43. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoeconomics. 2006;15:291-303.
44. Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. JAm Geriatr Soc. 2001;49:1685-1690.
45. Bodine PV, Seestaller-Wehr L, Kharode YP, et al. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. JCell Physiol. 2007;210:352-357.
46. Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A. 2005;102:17406-17411.
47. de Boer J, Wang HJ, Van Blitterswijk C. Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng. 2004;10:393-401.
48. de Boer J, Siddappa R, Gaspar C, et al. Wnt signaling inhibits osteogenic differentiationofhumanmesenchymalstemcells. Bone. 2004;34:818-826.
49. Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs. 2007;21:641-657.
50. Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry. 2006;18:43-48.
51. Levine J, Belmaker RH. Osteoporosis and schizophrenia. Am J Psychiatry. 2006;163:549-550.
52. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. NEngl JMed. 2004;350:2042-2049.
53. Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. JClin Psychiatry. 2003;64:761-766.
54. Sampson HW. Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health. 2002;26:292-298.
55. Moniz C. Alcohol and bone. Br Med Bull. 1994;50:67-75.
56. Kim MJ, Shim MS, Kim MK, et al. Effect of chronic alcohol ingestion on bone ineral density in males without liver cirrhosis. Korean J Intern Med. 2003;18:174-180.
57. Clark MK, Sowers MF, Dekordi F, et al. Bone mineral density and fractures among alcohol-dependent women in treatment and in recovery. Osteoporos Int. 2003;14:396-403.
58. Alexopoulos GS, Katz IR, Reynolds CF III, et al. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad MedSpecial Report. 2001.
59. Alexopoulos GS. Depressionin theelderly. Lancet. 2005;365:1961-1970.
60. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br JPsychiatry. 1999;174:297-303.
61. Ruhe HG, Huyser J, Swinkels JA, et al. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br JPsychiatry. 2006;189:309-316.
62. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol. 2005;45:1106-1122.
63. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337-344.
64. Leipzig RM, Hyer K, Elk K, et al. Attitudes toward working on interdisciplinary healthcare teams: a comparison by discipline. J Am Geriatr Soc. 2002;50:1141-1148.
65. Leslie WD, Derksen S, Prior HJ, et al. The interaction of ethnicity and chronic disease as risk factors for osteoporotic fractures: a comparison of Canadian aboriginals and non-aboriginals. Osteoporos Int. 2006;17:1358-1368.
66. Leslie WD, Derksen S, Metge C, et al. Fracture risk among First Nations people: a retrospective matched cohort study. CMAJ. 2004;171:869-873.
67. Mackey DC, Lui LY, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007;298:2381-2388.
68. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States. Arch Gen Psychiatry. 2004;61:1107-1115.
69. Osborn DP, Nazareth I, King MB. Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness: a cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol. 2007;42:787-793.
70. Roick C, Fritz-Wieacker A, Matschinger H, et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2007;42:268-276.
71. Saag K. Mend the mind, but mind the bones!: balancing benefits and potential skeletal risks of serotonin reuptake inhibitors. Arch Intern Med. 2007;167:1231-1232.
72. Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5- year risk of hip fracture in postmenopausal women. JAMA. 2007;298:2389-2398.